Trial Profile
A Phase III, Randomized, Open-Label Clinical Study of Napabucasin (GB201) in Combination With FOLFIRI Versus Napabucasin in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Nov 2021
Price :
$35
*
At a glance
- Drugs Napabucasin (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors 1Globe Biomedical
- 15 May 2018 New trial record